We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Rectal Colonization by Klebsiella Leads to Different Risks for Bacteremia

By LabMedica International staff writers
Posted on 20 Jul 2021
Print article
Image: GeneXpert System Xpert-CARBA test for the detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48 in 48 minutes (Photo courtesy of Cepheid)
Image: GeneXpert System Xpert-CARBA test for the detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48 in 48 minutes (Photo courtesy of Cepheid)
Carbapenem-resistant Enterobacterales (CRE) represent a threat for public health, being among the top multidrug-resistant pathogens. Intestinal colonization by CRE is a risk factor for developing subsequent infection.

In patients colonized by Klebsiella pneumoniae Carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp), the rate of bloodstream infections (BSI) ranges from 8% to 23%, and specific factors for development of subsequent BSI have been identified. K.pneumoniae typically colonizes human mucosal surfaces of the oropharynx and gastrointestinal (GI) tract.

Infectious Disease specialists at the Pisan University Hospital (Pisa, Italy) and their colleagues carried out single-center, longitudinal, prospective, observational study involving consecutive adult patients with rectal colonization by CR-Kp admitted to the hospital from December 2018 to December 2019. After initial screening, all hospitalized patients were monitored through periodical rectal swabs on a regular basis (once a week in non-ICU and twice a week in ICU wards).

Rectal swabs were processed using three sequential steps: 1) molecular detection of bla genes involved in carbapenems resistance, 2) culture and pathogen identification, and 3) antibiotic susceptibility testing. Molecular screening was performed by the GeneXpert System Xpert-CARBA test (Cepheid, Sunnyvale, CA, USA). Species identification was performed using MALDI-TOF MS (Bruker Daltonics, Bremen, Germany). Antimicrobial susceptibility tests were performed with the SensiTitre system (Thermo Fisher Scientific, Waltham, MA, USA). Isolates were subjected to whole-genome sequencing (WGS) with an Illumina MiSeq platform (Illumina, San Diego, CA, USA). Rectal carriers were classified as: NDM, KPC, VIM and OXA-48.

The scientists reported that of 677 rectal carriers, 382/677 (56.4%) were colonized by NDM, 247/677 (36.5%) by KPC, 39/677 (5.8%) by VIM and 9/677 (1.3%) by OXA-48. Dissemination of NDM-KP was mostly sustained by ST147, while KPC-kp belonged to ST512. A higher rate of BSI was documented in NDM-compared to KPC-rectal carriers: 59/382, (15.4%) versus 20/247, (8.1%). Incidence rates of BSI/100 patients/month were significantly higher in the NDM (22.33) than in the KPC group (9.56). On multivariate analysis, multi-site extra-intestinal colonization, solid organ transplantation, invasive procedures, intravascular device, ICU, cephalosporin, fluoroquinolones and NDM rectal colonization (odds ratio [OR] = 3.27) were independently associated with BSI.

The authors concluded that their patients colonized by NDM-Kp are at higher risk of bacteremia compared to those colonized by KPC-Kp and the carbapenemase type is strongly related to the specific ST. Thus, the findings may reflect an increased virulence of the ST147 clone of Kp. The study was published on June 27, 2021 in the journal Clinical Microbiology and Infection.

Related Links:
Pisan University Hospital
Cepheid
Bruker Daltonics
Thermo Fisher Scientific
Illumina


New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Automated Blood Typing System
IH-500 NEXT
New
LH ELISA
Luteinizing Hormone ELISA
New
Food Allergens Assay Kit
Allerquant 14G A

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Pathology

view channel
Image: The AI program analyzes a microscopy image from a tumor biopsy and determines what genes are likely turned on and off in the cells it contains (Photo courtesy of Olivier Gevaert/Stanford Medicine)

AI Tool ‘Sees’ Cancer Gene Signatures in Biopsy Images

To assess the type and severity of cancer, pathologists typically examine thin slices of a tumor biopsy under a microscope. However, to understand the genomic alterations driving the tumor's growth, scientists... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.